Mandag d. 4. januar invitere HC Andersen Capital på en opfølgning på 2020 samt en status på Covid og NGAL-test. BioPorto vil være repræsenteret af CEO Peter Mørch Eriksen

BioPorto aktien stiger 8% efter børsmeddelelse d.30/12:
1) BioPorto has obtained CE marking in the EU for its NGALds, a novel gRAD-based test for near-patient measurement of NGAL, and announces commercial launch
2) Its novel SARS-CoV-2 rapid test, also based on the gRAD-platform, is undergoing clinical testing at the University of California, Davis.